Targeting PVR (CD155) and its receptors in anti-tumor therapy

Paola Kučan Brlić*, Tihana Lenac Roviš, Guy Cinamon, Pini Tsukerman, Ofer Mandelboim, Stipan Jonjić

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

118 Scopus citations

Abstract

Poliovirus receptor (PVR, CD155) has recently been gaining scientific interest as a therapeutic target in the field of tumor immunology due to its prominent endogenous and immune functions. In contrast to healthy tissues, PVR is expressed at high levels in several human malignancies and seems to have protumorigenic and therapeutically attractive properties that are currently being investigated in the field of recombinant oncolytic virotherapy. More intriguingly, PVR participates in a considerable number of immunoregulatory functions through its interactions with activating and inhibitory immune cell receptors. These functions are often modified in the tumor microenvironment, contributing to tumor immunosuppression. Indeed, increasing evidence supports the rationale for developing strategies targeting these interactions, either in terms of checkpoint therapy (i.e., targeting inhibitory receptors) or in adoptive cell therapy, which targets PVR as a tumor marker.

Original languageAmerican English
Pages (from-to)51-63
Number of pages13
JournalCellular and Molecular Immunology
Volume16
Issue number1
DOIs
StatePublished - 1 Jan 2019

Bibliographical note

Publisher Copyright:
© 2018, The Chinese Society of Immunology and The University of Science and Technology of China, All rights reserved.

Keywords

  • PVR
  • TIGIT
  • checkpoint
  • immunotherapy
  • poliovirus
  • tumor

Fingerprint

Dive into the research topics of 'Targeting PVR (CD155) and its receptors in anti-tumor therapy'. Together they form a unique fingerprint.

Cite this